XML 39 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2
Xcede Technologies, Inc. Joint Venture (Details Textual) - USD ($)
1 Months Ended 3 Months Ended
Nov. 30, 2016
Nov. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Nov. 18, 2016
Debt Conversion, Converted Instrument, Amount     $ 3,500,000    
Extinguishment of Debt, Amount     5,500,000    
Gain (Loss) on Extinguishment of Debt     2,000,000    
Research and Development Expense, Total     196,000 $ 288,000  
Noncontrolling Interest [Member]          
Debt Conversion, Original Debt, Amount   $ 3,100,000      
Debt Conversion, Converted Instrument, Shares Issued   3,055,551      
Gain (Loss) on Extinguishment of Debt     $ 300,000    
Xcede Technologies inc [Member]          
Debt Instrument, Interest Rate, Stated Percentage 5.00% 5.00%      
Debt Instrument, Face Amount $ 5,500,000 $ 5,500,000      
Committed Investment In Cash $ 1,200,000 $ 1,200,000      
Debt Conversion, Converted Instrument, Shares Issued   5,394,120      
Capital Stock Financing Discount Percentage 20.00% 20.00%      
Noncontrolling Interest, Ownership Percentage by Parent     59.00%   59.00%
Noncontrolling Interest, Description     Noncontrolling interest represents the value of the Series A Preferred and common stock not owned by DBM plus 17% of cumulative losses of Xcede based on the 17% common stock ownership held by noncontrolling interests.    
Research and Development Expense, Total     $ 38,000    
Dynasil Biomedical [Member]          
Debt Conversion, Original Debt, Amount   $ 2,400,000      
Debt Conversion, Converted Instrument, Shares Issued   2,338,569      
Gain (Loss) on Extinguishment of Debt     $ 1,700,000    
External Funding [Member] | Convertible Debt [Member]          
Proceeds from Convertible Debt   $ 5,200,000      
Secured Promissory Note [Member] | Xcede Technologies inc [Member]          
Debt Instrument, Interest Rate, Stated Percentage 2.00% 2.00%      
Debt Instrument, Maturity Date Dec. 31, 2025        
Line of Credit Facility, Maximum Borrowing Capacity $ 1,500,000 $ 1,500,000      
Line of Credit Facility, Current Borrowing Capacity $ 500,000 $ 500,000      
Series B Preferred Stock [Member]          
Preferred Stock, Liquidation Preference Per Share     $ 1.27    
Preferred Stock, Liquidation Preference, Value     $ 200,000    
Series A Preferred Stock [Member]          
Preferred Stock, Liquidation Preference Per Share     $ 1.016    
Preferred Stock, Liquidation Preference, Value     $ 5,500,000    
Series A Preferred Stock [Member] | Noncontrolling Shareholders [Member]          
Preferred Stock, Liquidation Preference, Value     3,100,000    
Series A Preferred Stock [Member] | Dynasil Biomedical [Member]          
Preferred Stock, Liquidation Preference, Value     $ 2,400,000